Dean Rudge
Deputy Editor
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Krka Targets Sales Growth Under New Five-Year Plan – With EBITDA Margin To Regress
Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.
Aspen Continues Chinese Voyage By Acquiring Sandoz’s Local Operations
Aspen has underlined previously its commitment to building on its business in China, and now it has done so, picking up Sandoz’s local operations for up to €92.6m, while bringing in cash by offloading a quartet of anesthetics in Europe back to the firm.
Teva Shows Its Big Pharma Clout With $1.5bn Sanofi Deal
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second
ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.